EN IT

Reserved

Schwab International Equity ETF: 3 targets hit, residual capital runs on trailing stop

·46 min read
EXECUTIVE VIEW

At week 11 of a buy setup, the model's coverage is complete: all 3 statistical targets were hit by week 7. Residual capital runs with a trailing stop on the Inversion Point, now protecting a 4.78% accumulated gain. Technical analysis shows a daily double bottom in the 27 area.

Reserved analysis Subscribe to read →
Reserved

Schwab U.S. Broad Market ETF: mature trade, trailing stop active, residual position still running

·46 min read
EXECUTIVE VIEW

Week 11 of a buy trade with model coverage complete: all 3 statistical targets hit, trailing stop on the Inversion Point active, residual position running at +8% from entry. Weekly technical analysis shows early selling pressure.

Reserved analysis Subscribe to read →
Reserved

Schwab Emerging Markets · 10th week, all 3 model targets hit

·46 min read
EXECUTIVE VIEW

SCHE reaches week 10 of a buy signal — technical analysis confirms all 3 model targets hit. The confirmation week closed bearish, with weakness signals across the board. Trade setup at its final statistical window, now a trader's call.

Reserved analysis Subscribe to read →
Reserved

Starbucks enters a new buy signal as the sector weighs in

·45 min read
EXECUTIVE VIEW

Starbucks weekly technical analysis — week 1 of a buy signal with improving price action, but our model flags elevated-risk conditions. Trade setup requires selective entry.

Reserved analysis Subscribe to read →

Sabesp: +4.91% since signal, but the rebound complicates the picture

·45 min read
EXECUTIVE VIEW

Sabesp enters week 7 of a sell signal with a +4.91% gain since inception. This week closed sharply higher (+9.8%), with buy volume at 92% — a technical rebound that doesn't erase the bearish structure but demands a careful reading of the underlying indicators.

Read article →
Reserved

Sanofi: technical rebound at week 7, but the picture stays on edge

·45 min read
EXECUTIVE VIEW

At week 7 of the sell signal, Sanofi closes up 1.3% with buyers at 100% and CMF turning positive. MACD stays negative and momentum keeps deteriorating: the rebound is technical, the decline neither confirmed nor reversed yet.

Reserved analysis Subscribe to read →
Share WhatsApp Telegram Gmail LinkedIn